PharmaTher sees path to ketamine commercialization with no planned financing

PharmaTher (PHRRF) Holdings provided a corporate update to its shareholders, outlining a clear strategy to become the global leader in unlocking the pharmaceutical potential of ketamine. The Company has reached a pivotal stage in its growth, marked by a defined regulatory timeline and a strategic plan for commercial and international expansion for its ketamine-based products. The U.S. Food and Drug Administration has set its approval goal date of August 9, 2025, for the potential approval of PharmaTher’s ketamine product on or before this date. PharmaTher is fully-funded through its FDA approval goal date of August 9, 2025, and for its initial U.S. commercial launch. The Company has no plans for new equity or debt financing before the FDA approval goal date, underscoring its confidence in its current cash position and commitment to mitigating shareholder dilution through its existing capital structure.The manufacturing for the Company’s ketamine product is based in the United States, ensuring supply chain security, quality control, and readiness for commercial scale-up. PharmaTher is preparing for international regulatory submissions in Europe, the United Kingdom, Canada, Japan, and the APAC regions, expected to commence in the second half of 2025. The Company is actively exploring the expansion of ketamine’s therapeutic applications, inspired by growing bipartisan support for psychedelic-assisted therapies, including recent federal initiatives on Kennedy-backed Make America Healthy Again movement. The Company has already submitted pre-INDs and INDs for ketamine in indications such as Parkinson’s disease, ALS, CRPS, and for novel delivery systems, including an on-body wearable pump and microneedle patch.